CA
NZ
UK
AU
IND
US
No company-specific catalyst was confirmed in the filings reviewed, and the stock fell 3.25% on volume about 20 times average. The 52-week range of USD 0.58 to USD 209.50 means the high is about 333 times the current price, which suggests reverse splits, and …
Alumis (NASDAQ:ALMS) shares rose in today's session after the company presented new data from its Phase 3 ONWARD clinical program for envudeucitinib, an oral pill being developed for moderate to severe plaque psoriasis. The results were presented at the Fall Clinical Dermatology Conference 2026.
Arcutis Biotherapeutics (NASDAQ:ARQT) shares rose sharply in today's session after the company presented new data on Zoryve, its roflumilast cream, at the EADV Congress and the Fall Clinical Dermatology Conference 2026. A Phase 2 trial of Zoryve 0.05% cream in infants aged three to …
Basel Medical Group (NASDAQ:BMGL), aPenny Stocktrading near $3.59, was little changed in today's session after pricing a registered direct offering of 6,000,000 units at $1.33 per unit, a level well below where shares have recently traded. The offering is expected to generate gross proceeds …
bioAffinity Technologies (NASDAQ:BIAF), aPenny Stocktrading near $4.79, fell sharply in today's session following news of a stock and warrant sale intended to raise approximately $4 million for the company. The decline reflects a common pattern for small biotech names, where new share issuance can …
Eli Lilly (NYSE:LLY) shares rose in today's session after the company presented new exploratory data from its TOGETHER-PsO trial, which studies the combined use of Taltz, its psoriasis treatment, and Zepbound, its weight-loss drug, in patients who have both conditions. The data was presented …
Glaukos (NYSE:GKOS) shares held steady in today's session after the company announced positive topline results from a Phase 4 trial evaluating its iDose TR implant used alongside cataract surgery in patients with open-angle glaucoma or high eye pressure. The study compared this combination against …
Johnson & Johnson (NYSE:JNJ) shares climbed in today's session after the company presented new two-year results from its Phase 3 ICONIC-LEAD study of Icotyde, a targeted oral peptide treatment for moderate to severe plaque psoriasis. The data was presented at the Fall Clinical Dermatology …
Milestone Pharmaceuticals (NASDAQ:MIST), aPenny Stocktrading near $0.76, rose sharply in today's session after announcing that the first patient in Europe has been enrolled in ReVeRA-301, its Phase 3 trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate, a fast and irregular …
Natera (NASDAQ:NTRA) shares rose in today's session after the company announced that its multi-cancer early detection assay received Breakthrough Device designation from the FDA. The designation is intended for technologies that could offer meaningfully better diagnosis or treatment for life-threatening conditions, and it allows …
Please wait processing your request...